Alexander Roesch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2765253/publications.pdf

Version: 2024-02-01

76 papers

6,370 citations

147566 31 h-index 77 g-index

82 all docs 82 docs citations

times ranked

82

11380 citing authors

#	Article	IF	CITATIONS
1	A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth. Cell, 2010, 141, 583-594.	13.5	1,052
2	Melanoma. Lancet, The, 2018, 392, 971-984.	6.3	1,016
3	Cancer stem cell definitions and terminology: the devil is in the details. Nature Reviews Cancer, 2012, 12, 767-775.	12.8	599
4	Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells. Cancer Cell, 2013, 23, 811-825.	7.7	553
5	Melanoma. Nature Reviews Disease Primers, 2015, 1, 15003.	18.1	417
6	Metastatic status of sentinel lymph nodes in melanoma determined noninvasively with multispectral optoacoustic imaging. Science Translational Medicine, 2015, 7, 317ra199.	5.8	239
7	Immunotherapy in melanoma: Recent advances and future directions. European Journal of Surgical Oncology, 2017, 43, 604-611.	0.5	216
8	Targeting hyperactivation of the <scp>AKT</scp> survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Medicine, 2013, 2, 76-85.	1.3	126
9	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Reports, 2017, 21, 1953-1967.	2.9	117
10	Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma. Oncogene, 2015, 34, 2951-2957.	2.6	99
11	Transcriptional Profiling of Human Endogenous Retrovirus Group HERV-K(HML-2) Loci in Melanoma. Genome Biology and Evolution, 2013, 5, 307-328.	1.1	94
12	RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas. Oncogene, 2018, 37, 6136-6151.	2.6	91
13	Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. European Journal of Cancer, 2016, 67, 66-72.	1.3	90
14	Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene, 2010, 29, 6115-6124.	2.6	83
15	Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas. Modern Pathology, 2005, 18, 1249-1257.	2.9	76
16	Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma. European Journal of Cancer, 2017, 81, 36-44.	1.3	76
17	Aetiology, comorbidities and cofactors of chronic leg ulcers: retrospective evaluation of 1 000 patients from 10 specialised dermatological wound care centers in Germany. International Wound Journal, 2016, 13, 821-828.	1.3	70
18	RBP2â€H1/JARID1B is a transcriptional regulator with a tumor suppressive potential in melanoma cells. International Journal of Cancer, 2008, 122, 1047-1057.	2.3	69

#	Article	IF	Citations
19	Targeted next generation sequencing of mucosal melanomas identifies frequent <i>NF1</i> and <i>RAS</i> mutations. Oncotarget, 2017, 8, 40683-40692.	0.8	69
20	Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency. Cancer Research, 2016, 76, 4347-4358.	0.4	63
21	Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis. European Journal of Cancer, 2020, 131, 18-26.	1.3	50
22	JARID1B Enables Transit between Distinct States of the Stem-like Cell Population in Oral Cancers. Cancer Research, 2016, 76, 5538-5549.	0.4	46
23	Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma. European Journal of Cancer, 2016, 59, 109-112.	1.3	45
24	Re-Expression of the Retinoblastoma-Binding Protein 2-Homolog 1 Reveals Tumor-Suppressive Functions in Highly Metastatic Melanoma Cells. Journal of Investigative Dermatology, 2006, 126, 1850-1859.	0.3	41
25	Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations. Experimental Dermatology, 2015, 24, 155-157.	1.4	41
26	Actinic keratoses treated with cold atmospheric plasma. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e37-e39.	1.3	41
27	Discrimination between gene expression patterns in the invasive margin and the tumour core of malignant melanomas. Melanoma Research, 2003, 13, 503-509.	0.6	39
28	Ephrin-B2 is differentially expressed in the intestinal epithelium in Crohn's disease and contributes to accelerated epithelial wound healingin vitro. World Journal of Gastroenterology, 2005, 11, 4024.	1.4	38
29	Identification of new genes associated with melanoma. Experimental Dermatology, 2011, 20, 502-507.	1.4	37
30	Dermatoscopy of "dysplastic nevi": a beacon in diagnostic darkness. European Journal of Dermatology, 2006, 16, 479-93.	0.3	37
31	Clinical and genetic analysis of melanomas arising in acral sites. European Journal of Cancer, 2019, 119, 66-76.	1.3	34
32	From Cancer Stem Cells to Tumor Maintenance in Melanoma. Journal of Investigative Dermatology, 2011, 131, 1600-1604.	0.3	33
33	Ephrin-B reverse signaling induces expression of wound healing associated genes in IEC-6 intestinal epithelial cells. World Journal of Gastroenterology, 2005, 11, 4511.	1.4	33
34	Overexpression and hyperphosphorylation of retinoblastoma protein in the progression of malignant melanoma. Modern Pathology, 2005, 18, 565-572.	2.9	32
35	Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho. Clinical Cancer Research, 2017, 23, 3181-3190.	3.2	30
36	The role of Orai–STIM calcium channels in melanocytes and melanoma. Journal of Physiology, 2016, 594, 2825-2835.	1.3	29

#	Article	IF	CITATIONS
37	Cloning and characterization of the human FCRL2 gene. Genomics, 2005, 85, 264-272.	1.3	27
38	Bowen's Disease on Porokeratotic Eccrine Ostial and Dermal Duct Nevus. Dermatologic Surgery, 2007, 33, 496-499.	0.4	27
39	Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma Cells. Journal of Investigative Dermatology, 2019, 139, 2506-2516.e10.	0.3	27
40	Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma. JCO Precision Oncology, 2019, 3, 1-10.	1.5	25
41	Discrimination of Melanocytic Tumors by cDNA Array Hybridization of Tissues Prepared by Laser Pressure Catapulting. Journal of Investigative Dermatology, 2004, 122, 361-368.	0.3	24
42	SECTM1 Produced by Tumor Cells Attracts Human Monocytes via CD7-Mediated Activation of the PI3K Pathway. Journal of Investigative Dermatology, 2014, 134, 1108-1118.	0.3	24
43	Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer. Cancers, 2020, 12, 353.	1.7	24
44	Severe contact urticaria to guar gum included as gelling agent in a local anaesthetic. Contact Dermatitis, 2005, 52, 307-308.	0.8	23
45	Patients with pyoderma gangrenosum – analyses of the German <scp>DRG</scp> data from 2012. International Wound Journal, 2016, 13, 951-956.	1.3	21
46	Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma. European Journal of Cancer, 2019, 109, 137-153.	1.3	20
47	Persister state-directed transitioning and vulnerability in melanoma. Nature Communications, 2022, 13,	5.8	20
48	Computer assisted learning in medicine: a long-term evaluation of the  Practical Training Programme Dermatology 2000'. Informatics for Health and Social Care, 2003, 28, 147-159.	1.0	19
49	Loss of dipeptidyl peptidase IV immunostaining discriminates malignant melanomas from deep penetrating nevi. Modern Pathology, 2006, 19, 1378-1385.	2.9	19
50	Combining $\langle scp \rangle BRAF \langle sup \rangle V \langle sup \rangle \langle scp \rangle \langle sup \rangle 600E \langle sup \rangle$ inhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanoma. Experimental Dermatology, 2015, 24, 709-710.	1.4	19
51	Gene Expression Profile Changes between Melanoma Metastases and their Daughter Cell Lines: Implication for Vaccination Protocols. Journal of Investigative Dermatology, 2005, 124, 401-404.	0.3	17
52	The predictive and prognostic significance of cellâ€free DNA concentration in melanoma. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 387-395.	1.3	17
53	Leptomeningeal disease from melanoma—Poor prognosis despite new therapeutic modalities. European Journal of Cancer, 2021, 148, 395-404.	1.3	16
54	Coronavirus disease 2019 vaccine mimics lymph node metastases in patients undergoing skin cancer follow-up: A monocentre study. European Journal of Cancer, 2021, 154, 167-174.	1.3	15

#	Article	IF	CITATIONS
55	Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases. European Journal of Cancer, 2021, 152, 139-154.	1.3	13
56	Integrative Genomic Analyses of Patient-Matched Intracranial and Extracranial Metastases Reveal a Novel Brain-Specific Landscape of Genetic Variants in Driver Genes of Malignant Melanoma. Cancers, 2021, 13, 731.	1.7	12
57	Trametinib-Induced Remission of an <i>MEK1</i> Hutated Langerhans Cell Histiocytosis. JCO Precision Oncology, 2017, 1, 1-5.	1.5	11
58	Elimination of a Community-Acquired Methicillin-Resistant Staphylococcus aureus Infection in a Nurse With Atopic Dermatitis. Archives of Dermatology, 2005, 141, 1520-2.	1.7	10
59	Efficacy of cold atmospheric plasma vs. diclofenac 3% gel in patients with actinic keratoses: a prospective, randomized and raterâ€blinded study (ACTICAP). Journal of the European Academy of Dermatology and Venereology, 2020, 34, e844-e846.	1.3	10
60	Congenital Cartilaginous Rests of the Neck (Wattles). Dermatologic Surgery, 2006, 31, 1349-1350.	0.4	9
61	In vivo and ex vivo MR imaging of slowly cycling melanoma cells. Magnetic Resonance in Medicine, 2011, 66, 1362-1373.	1.9	9
62	Melanoma stem cells. JDDG - Journal of the German Society of Dermatology, 2015, 13, 118-124.	0.4	9
63	Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma. Frontiers in Oncology, 2021, 11, 741993.	1.3	9
64	Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib. Clinical Cancer Research, 2021, 27, 4500-4510.	3.2	8
65	BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment. Cancer Research, 2022, 82, 264-277.	0.4	8
66	Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population. JDDG - Journal of the German Society of Dermatology, 2008, 6, 292-297.	0.4	7
67	Melanoma Differentiation Trajectories Determine Sensitivity toward Pre-Existing CD8+ Tumor-Infiltrating Lymphocytes. Journal of Investigative Dermatology, 2021, 141, 2480-2489.	0.3	7
68	Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition – Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry. Frontiers in Oncology, 2021, 11, 725549.	1.3	6
69	Dysplastischer melanozyt�rer N�vus. Hautarzt, 2003, 54, 871-885.	1.2	5
70	Zelkovamycin is an OXPHOS Inhibitory Member of the Argyrin Natural Product Family. Chemistry - A European Journal, 2020, 26, 8524-8531.	1.7	5
71	Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma. European Journal of Cancer, 2017, 83, 142-145.	1.3	4
72	Post-traumatic iatrogenic aggravation of eruptive collagenomas in a child. European Journal of Dermatology, 2006, 16, 196-7.	0.3	3

#	Article	IF	CITATIONS
73	Fatal swelling of the groin – Clear cell sarcoma: a rare but important differential diagnosis to malignant melanoma. JDDG - Journal of the German Society of Dermatology, 2020, 18, 1165-1168.	0.4	2
74	Management of partial and nonâ€responding cutaneous squamous cell carcinoma. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 29-34.	1.3	2
75	Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia: divergent outcomes in two men treated with PDâ€1 inhibitors. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 41-44.	1.3	1
76	Tumorstammzellen im Melanom. JDDG - Journal of the German Society of Dermatology, 2015, 13, 118-124.	0.4	0